DK142802B - Fremgangsmåde til fremstilling af terapeutiske præparater til indføring i mavesækken. - Google Patents

Fremgangsmåde til fremstilling af terapeutiske præparater til indføring i mavesækken. Download PDF

Info

Publication number: DK142802B
Authority: DK; Denmark
Prior art keywords: stomach; parts; coated; preparation; gastric juice
Prior art date: 1974-03-12

Application number

DK97875AA

Other languages

Danish (da)

English (en)

Other versions

DK97875A (fr

DK142802C (fr

Inventor

Sumio Watanabe

Masanori Kayano

Yoshio Ishino

Kohei Miyao

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1974-03-12

Filing date

1975-03-11

Publication date

1981-02-02

1975-03-11 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1975-09-13 Publication of DK97875A publication Critical patent/DK97875A/da

1981-02-02 Publication of DK142802B publication Critical patent/DK142802B/da

1981-09-21 Application granted granted Critical

1981-09-21 Publication of DK142802C publication Critical patent/DK142802C/da

Links

239000000203 mixture Substances 0.000 title description 23
210000002784 stomach Anatomy 0.000 title description 22
238000002360 preparation method Methods 0.000 title description 15
230000001225 therapeutic effect Effects 0.000 title description 11
238000000034 method Methods 0.000 title description 10
239000004480 active ingredient Substances 0.000 description 17
210000004051 gastric juice Anatomy 0.000 description 17
239000011248 coating agent Substances 0.000 description 14
238000000576 coating method Methods 0.000 description 14
239000001856 Ethyl cellulose Substances 0.000 description 10
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 10
235000019325 ethyl cellulose Nutrition 0.000 description 10
229920001249 ethyl cellulose Polymers 0.000 description 10
ZEEXVYNJSAWEML-UHFFFAOYSA-N 3-[4-(4-methylphenyl)sulfanyl-3-nitrophenyl]prop-2-enoic acid Chemical compound C1=CC(C)=CC=C1SC1=CC=C(C=CC(O)=O)C=C1[N+]([O-])=O ZEEXVYNJSAWEML-UHFFFAOYSA-N 0.000 description 9
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 9
VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 9
229960001377 benactyzine hydrochloride Drugs 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
235000000346 sugar Nutrition 0.000 description 8
241000209094 Oryza Species 0.000 description 7
235000007164 Oryza sativa Nutrition 0.000 description 7
239000002775 capsule Substances 0.000 description 7
239000000463 material Substances 0.000 description 7
235000009566 rice Nutrition 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000007788 liquid Substances 0.000 description 6
235000013339 cereals Nutrition 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000000758 substrate Substances 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229920003145 methacrylic acid copolymer Polymers 0.000 description 4
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 3
MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 description 3
229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
229940081734 cellulose acetate phthalate Drugs 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 3
229940117841 methacrylic acid copolymer Drugs 0.000 description 3
230000004962 physiological condition Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000007921 spray Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000007902 hard capsule Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000031700 light absorption Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229920006327 polystyrene foam Polymers 0.000 description 2
210000001187 pylorus Anatomy 0.000 description 2
235000020374 simple syrup Nutrition 0.000 description 2
238000005303 weighing Methods 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229920002126 Acrylic acid copolymer Polymers 0.000 description 1
241001342895 Chorus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
241000482268 Zea mays subsp. mays Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002467 anti-pepsin effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
238000000465 moulding Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
239000011800 void material Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Landscapes

Health & Medical Sciences (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)

DK97875AA 1974-03-12 1975-03-11 Fremgangsmåde til fremstilling af terapeutiske præparater til indføring i mavesækken. DK142802B (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2767374A JPS5512411B2 (fr)	1974-03-12	1974-03-12
JP2767374		1974-03-12

Publications (3)

Publication Number	Publication Date
DK97875A DK97875A (fr)	1975-09-13
DK142802B true DK142802B (da)	1981-02-02
DK142802C DK142802C (fr)	1981-09-21

Family

ID=12227459

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97875AA DK142802B (da)	1974-03-12	1975-03-11	Fremgangsmåde til fremstilling af terapeutiske præparater til indføring i mavesækken.

Country Status (12)

Country	Link
US (1)	US3976764A (fr)
JP (1)	JPS5512411B2 (fr)
BE (1)	BE826498A (fr)
CA (1)	CA1054056A (fr)
CH (1)	CH604719A5 (fr)
DE (1)	DE2510620C2 (fr)
DK (1)	DK142802B (fr)
ES (1)	ES435500A1 (fr)
FR (1)	FR2263744B1 (fr)
GB (1)	GB1507521A (fr)
NL (1)	NL7502952A (fr)
SE (1)	SE409286B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1985003437A1 (fr) *	1984-02-10	1985-08-15	A/S Alfred Benzon	Formulation de dosage d'unites multiples enrobees a liberation par diffusion

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH630257A5 (en) *	1975-03-17	1982-06-15	Hoffmann La Roche	Sustained release formulation
US4167558A (en) *	1976-02-13	1979-09-11	Hoffmann-La Roche Inc.	Novel sustained release tablet formulations
US4140755A (en) *	1976-02-13	1979-02-20	Hoffmann-La Roche Inc.	Sustained release tablet formulations
US4207890A (en) *	1977-01-04	1980-06-17	Mcneilab, Inc.	Drug-dispensing device and method
JPS6024767B2 (ja) *	1979-08-24	1985-06-14	塩野義製薬株式会社	腸溶性硬カプセル剤
ATE34300T1 (de) *	1981-07-15	1988-06-15	Key Pharma	Theophyllin mit verlaengerter abgabe.
US4451260A (en) *	1982-03-26	1984-05-29	Minnesota Mining And Manufacturing Company	Sustained release oral medicinal delivery device
JPS5953410A (ja) *	1982-09-20	1984-03-28	Fujisawa Pharmaceut Co Ltd	新型ソフトカプセル剤
JPS59193831A (ja) *	1983-04-18	1984-11-02	Sankyo Co Ltd	腸溶性製剤の製造法
US4505890A (en) *	1983-06-30	1985-03-19	E. R. Squibb & Sons, Inc.	Controlled release formulation and method
SE457505B (sv) *	1984-01-10	1989-01-09	Lejus Medical Ab	Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4610870A (en) *	1984-10-05	1986-09-09	E. R. Squibb & Sons, Inc.	Controlled release formulation
JPS61107782U (fr) *	1984-12-19	1986-07-08
US4735804A (en) *	1985-05-10	1988-04-05	Merck & Co., Inc.	Drug delivery device which can be retained in the stomach for a controlled period of time
US4758436A (en) *	1985-05-29	1988-07-19	Merck & Co., Inc.	Drug delivery device which can be retained in the stomach for a controlled period of time
US4767627A (en) *	1985-05-29	1988-08-30	Merck & Co., Inc.	Drug delivery device which can be retained in the stomach for a controlled period of time
US4666705A (en) *	1985-06-03	1987-05-19	E. R. Squibb & Sons, Inc.	Controlled release formulation
US4756911A (en) *	1986-04-16	1988-07-12	E. R. Squibb & Sons, Inc.	Controlled release formulation
US4814178A (en) *	1987-07-01	1989-03-21	Sanford Bolton	Floating sustained release therapeutic compositions
DE3803482A1 (de) *	1988-02-05	1989-08-17	Lohmann Therapie Syst Lts	Schwimmfaehiges orales therapeutisches system
JPH082781B2 (ja) *	1988-10-18	1996-01-17	嘉明川島	中空顆粒状医薬及びその製法
EP0536277A1 (fr) *	1990-06-25	1993-04-14	The Du Pont Merck Pharmaceutical Company	Suspension d'hydrochlorure d'amantadine possedant des caracteristiques de dissolution ameliorees, utilisee dans la preparation de capsules de gelatine souples
US5232704A (en) *	1990-12-19	1993-08-03	G. D. Searle & Co.	Sustained release, bilayer buoyant dosage form
US5198229A (en) *	1991-06-05	1993-03-30	Alza Corporation	Self-retaining gastrointestinal delivery device
US5314696A (en) *	1991-06-27	1994-05-24	Paulos Manley A	Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
DE4406424A1 (de) *	1994-02-28	1995-08-31	Bayer Ag	Expandierbare Arzneiformen
JP2671257B2 (ja) *	1995-07-13	1997-10-29	エーザイ株式会社	溶解遅延性ゼラチン製剤組成物
SE9702533D0 (sv)	1997-07-01	1997-07-01	Astra Ab	New oral formulation
IN186245B (fr)	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
EP1063973B1 (fr)	1998-03-19	2016-11-16	Bristol-Myers Squibb Company	Systeme d'apport a liberation lente biphasique destine a des medicaments a solubilite elevee et procede associe
EP1245227A1 (fr) *	2001-03-31	2002-10-02	Jagotec Ag	Comprimé pharmaceutique flottant dans l'estomac destiné à la libération programmée du principe actif et procédé pour produire le matériel flottant compris dans le comprimé
US20030203027A1 (en) *	2002-04-26	2003-10-30	Ethicon, Inc.	Coating technique for deposition of drug substance on a substrate
US20040086566A1 (en) *	2002-11-04	2004-05-06	Alpharma, Inc.	Waxy matrix dosage forms
US7485322B2 (en) *	2002-12-24	2009-02-03	Lek Pharmaceuticals D.D.	Modified release pharmaceutical composition
CA2516327C (fr) *	2003-02-21	2012-04-17	Lek Pharmaceuticals D.D	Systeme therapeutique a base d'amoxicilline et d'acide clavulanique
WO2005046655A1 (fr) *	2003-11-04	2005-05-26	Shire Laboratories, Inc.	Liberation prolongee de molecules actives d'un point de vue pharmacologique positivement chargees a partir d'une matrice contenant des polymeres avec des atomes d'oxygene polarises
AU2007323018B2 (en) *	2006-09-04	2011-02-03	Panacea Biotec Limited	Programmable buoyant delivery technology
WO2009087665A2 (fr) *	2007-12-11	2009-07-16	Vishwanath Sudhir Nande	Nouveau système d'administration de médicament à rétention gastrique
GB2460915B (en)	2008-06-16	2011-05-25	Biovascular Inc	Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
JP2012500230A (ja) *	2008-08-18	2012-01-05	北京天衡▲薬▼物研究院	胃内滞留薬物放出システム及びその製造方法と使用
FR2945947B1 (fr)	2009-05-29	2011-07-29	Flamel Tech Sa	Compositions pharmaceutiques flottantes a liberation controlee
FR2945945B1 (fr) *	2009-05-29	2011-07-29	Flamel Tech Sa	Procede de preparation de particules creuses et leurs applications
JP5594484B2 (ja) *	2009-07-06	2014-09-24	杏林製薬株式会社	中空構造を有する錠剤
CN105726460A (zh)	2010-07-05	2016-07-06	雅戈泰克股份公司	剂型
WO2014014348A1 (fr) *	2012-07-16	2014-01-23	APET Holding B.V.	Système d'administration pharmacologique à rétention gastrique
WO2013009186A1 (fr) *	2011-07-14	2013-01-17	APET Holding B.V.	Compositions de nicotinamide et leur utilisation thérapeutique
CA2851765C (fr)	2011-10-11	2017-08-15	Ranbaxy Laboratories Limited	Systeme de dosage de retention gastrique et procede de preparation de celui-ci
DK2719376T3 (en)	2012-10-12	2015-06-15	Omya Int Ag	Gastroretentiv drug formulation and delivery systems and their method of preparation by the use of functional calcium carbonate
US20170266112A1 (en)	2014-06-11	2017-09-21	Massachusetts Institute Of Technology	Residence structures and related methods
RU2766335C2 (ru)	2014-06-11	2022-03-15	Массачусетс Инститьют Оф Текнолоджи	Удерживаемые структуры и связанные способы
EP3034070A1 (fr)	2014-12-18	2016-06-22	Omya International AG	Procédé pour la production d'un système d'administration pharmaceutique
CN104706613B (zh) *	2015-03-20	2018-01-16	华侨大学	一种胃漂浮空心缓释片的制备方法
EP3069713A1 (fr)	2015-03-20	2016-09-21	Omya International AG	Forme posologique dispersible
EP3288604B1 (fr)	2015-05-01	2021-11-17	Massachusetts Institute of Technology	Dispositifs d'induction à mémoire de forme pouvant être déclenchés
CN108472249A (zh)	2015-10-23	2018-08-31	林德拉有限公司	用于治疗剂缓释的胃驻留系统及其使用方法
EP3386488B1 (fr)	2015-12-08	2023-09-06	Lyndra Therapeutics, Inc.	Configurations géométriques de systèmes à résidence gastrique
AU2017235598A1 (en) *	2016-03-18	2018-08-09	Grünenthal GmbH	Floating pharmaceutical dosage form
CN109310639A (zh)	2016-05-27	2019-02-05	林德拉有限公司	用于胃驻留系统的材料结构
EP3269361A1 (fr)	2016-07-14	2018-01-17	Omya International AG	Forme posologique
JP2019532947A (ja)	2016-09-30	2019-11-14	リンドラ，インコーポレイティド	アダマンタン系薬物の持続的送達のための胃内滞留システム
EP3634382A4 (fr)	2017-06-09	2021-07-07	Lyndra Therapeutics, Inc.	Systèmes gastriques à demeure avec films modulant le taux de libération
JP7624750B2 (ja) *	2020-03-02	2025-01-31	クラフトヘルスプライベートリミテッド	持続的薬物放出のための経口剤形
EP4008509B1 (fr) *	2020-10-14	2023-06-07	Bichsel, Hannes	Grains biogranulaires expansés
WO2023166225A1 (fr) *	2022-03-04	2023-09-07	APET Holding B.V.	Formulations d'enzyme digestive

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3418999A (en) *	1964-02-12	1968-12-31	Donald W. Davis	Method of swallowing a pill
FR1454013A (fr) *	1965-08-18	1966-07-22	Pluripharm	Mode de présentation de deux médicaments associés
US3870790A (en) *	1970-01-22	1975-03-11	Forest Laboratories	Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose

1974
- 1974-03-12 JP JP2767374A patent/JPS5512411B2/ja not_active Expired
1975
- 1975-03-10 BE BE154189A patent/BE826498A/fr not_active IP Right Cessation
- 1975-03-10 FR FR7507336A patent/FR2263744B1/fr not_active Expired
- 1975-03-11 SE SE7502725A patent/SE409286B/xx not_active IP Right Cessation
- 1975-03-11 DE DE2510620A patent/DE2510620C2/de not_active Expired
- 1975-03-11 US US05/557,408 patent/US3976764A/en not_active Expired - Lifetime
- 1975-03-11 DK DK97875AA patent/DK142802B/da not_active IP Right Cessation
- 1975-03-11 ES ES435500A patent/ES435500A1/es not_active Expired
- 1975-03-12 CH CH315475A patent/CH604719A5/xx not_active IP Right Cessation
- 1975-03-12 CA CA221,903A patent/CA1054056A/fr not_active Expired
- 1975-03-12 NL NL7502952A patent/NL7502952A/xx not_active Application Discontinuation
- 1975-03-12 GB GB10214/75A patent/GB1507521A/en not_active Expired

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1985003437A1 (fr) *	1984-02-10	1985-08-15	A/S Alfred Benzon	Formulation de dosage d'unites multiples enrobees a liberation par diffusion

Also Published As

Publication number	Publication date
NL7502952A (nl)	1975-09-16
BE826498A (fr)	1975-06-30
DE2510620A1 (de)	1975-09-18
CH604719A5 (fr)	1978-09-15
FR2263744B1 (fr)	1978-11-24
DK97875A (fr)	1975-09-13
JPS50121418A (fr)	1975-09-23
JPS5512411B2 (fr)	1980-04-02
SE7502725L (fr)	1975-09-15
GB1507521A (en)	1978-04-19
CA1054056A (fr)	1979-05-08
ES435500A1 (es)	1977-02-01
US3976764A (en)	1976-08-24
DK142802C (fr)	1981-09-21
DE2510620C2 (de)	1984-01-05
FR2263744A1 (fr)	1975-10-10
SE409286B (sv)	1979-08-13

Legal Events

Date	Code	Title	Description
1993-11-22	PBP	Patent lapsed

Publication	Publication Date	Title
CA1054056A (fr)	1979-05-08	Preparation therapeutique solide sejournant dans l'estomac
EP0235718B1 (fr)	1991-10-30	Granule retenu dans l'estomac
US2928770A (en)	1960-03-15	Sustained action pill
US4587118A (en)	1986-05-06	Dry sustained release theophylline oral formulation
CA2342340C (fr)	2006-08-29	Nouvelles formulations administrees par voie orale et a liberation prolongee
BE1004882A3 (fr)	1993-02-16	Forme posologique pharmaceutique solide orale a liberation programmee.
RU2477126C2 (ru)	2013-03-10	Глюкозинолаты и бета-тиоглюкозидазы, покрытые энтеросолюбильной оболочкой
RU2095054C1 (ru)	1997-11-10	Твердая лекарственная форма для орального введения
US4935247A (en)	1990-06-19	Composition for the oral administration of pharmaceuticals
AU783911B2 (en)	2005-12-22	Coated solid dosage forms
BG63152B1 (bg)	2001-05-31	Дозирани форми с контролирано освобождаване на азитромицин
JPS6116368B2 (fr)	1986-04-30
US5277916A (en)	1994-01-11	Tetracycline dosage form
GB2101484A (en)	1983-01-19	Oral dipyridamole compositions
DK151608B (da)	1987-12-21	Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
PL188834B1 (pl)	2005-04-29	Farmaceutyczne formulacje zawierające tramadol lub jego fizjologicznie akceptowane sole oraz sposóbwytwarzania tych formulacji
JPH0256418A (ja)	1990-02-26	新規医薬製剤およびその製造方法
PT612520E (pt)	2001-12-28	Dispositivos de administracao por desintegracao osmotica desagregada pelo ph
AU2018202652A1 (en)	2018-05-10	Gastro-retentive drug delivery system
NO175132B (no)	1994-05-30	Fremgangsmåte ved fremstilling av legemiddel inneholdende Dipyridamol eller Mopidamol og 0-acetylsalisyre samt deres fysiologisk fordragelige salter
EP0425699B1 (fr)	1994-08-17	Preparation orale pouvant etre liberee dans une region appropriee de l'intestin
AU684786B2 (en)	1998-01-08	A drug delivery composition for alpha-adreno receptor blocking agents
WO2020060426A1 (fr)	2020-03-26	Préparation orale contenant du butyrate de sodium
CA2533178C (fr)	2014-03-11	Produit antibiotique, son utilisation et sa formulation
NO774400L (no)	1978-07-26	Fremgangsmaate til fremstilling av farmasoeytiske sammensetninger

DK142802B - Fremgangsmåde til fremstilling af terapeutiske præparater til indføring i mavesækken. - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (3)

Family

ID=12227459

Family Applications (1)

Country Status (12)

Cited By (1)

Families Citing this family (64)

Family Cites Families (3)

Cited By (1)

Also Published As

Similar Documents

Legal Events